Anmeldung erfolgt in Kürze...
Details werden geladen...
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide) | The Manila Times
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ('Lantheus” or 'Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs).
Ähnliche Seiten
Cingulate Receives Complete Response Letter from FDA for CTx-1301 | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/cingulate-receives-complete-response-letter-from-fda-for-ctx-1301/2356795
Cingulate Receives FDA Complete Response Letter For ADHD Drug CTx-1301 | 02.06.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/cingulate-receives-fda-complete-response-letter-for-adhd-drug-ctx-1301-1036217422
Swedish Orphan Biovitrum AB: Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
https://www.finanznachrichten.de/nachrichten-2026-06/68879447-swedish-orphan-biovitrum-ab-sobi-receives-complete-response-letter-from-fda-for-nasp-nanoencapsulated-sirolimus-plus-pegadricase-008.htm
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer | The Manila Times
https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/roche-receives-fda-approval-for-the-first-companion-diagnostic-to-assess-pten-protein-in-people-living-with-prostate-cancer/2364692